» Articles » PMID: 25202235

Guanylyl Cyclase/natriuretic Peptide Receptor-A Signaling Antagonizes Phosphoinositide Hydrolysis, Ca(2+) Release, and Activation of Protein Kinase C

Overview
Specialty Molecular Biology
Date 2014 Sep 10
PMID 25202235
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Thus far, three related natriuretic peptides (NPs) and three distinct sub-types of cognate NP receptors have been identified and characterized based on the specific ligand binding affinities, guanylyl cyclase activity, and generation of intracellular cGMP. Atrial and brain natriuretic peptides (ANP and BNP) specifically bind and activate guanylyl cyclase/natriuretic peptide receptor-A (GC-A/NPRA), and C-type natriuretic peptide (CNP) shows specificity to activate guanylyl cyclase/natriuretic peptide receptor-B (GC-B/NPRB). All three NPs bind to natriuretic peptide receptor-C (NPRC), which is also known as clearance or silent receptor. The NPRA is considered the principal biologically active receptor of NP family; however, the molecular signaling mechanisms of NP receptors are not well understood. The activation of NPRA and NPRB produces the intracellular second messenger cGMP, which serves as the major signaling molecule of all three NPs. The activation of NPRB in response to CNP also produces the intracellular cGMP; however, at lower magnitude than that of NPRA, which is activated by ANP and BNP. In addition to enhanced accumulation of intracellular cGMP in response to all three NPs, the levels of cAMP, Ca(2+) and inositol triphosphate (IP3) have also been reported to be altered in different cells and tissue types. Interestingly, ANP has been found to lower the concentrations of cAMP, Ca(2+), and IP3; however, NPRC has been proposed to increase the levels of these metabolic signaling molecules. The mechanistic studies of decreased and/or increased levels of cAMP, Ca(2+), and IP3 in response to NPs and their receptors have not yet been clearly established. This review focuses on the signaling mechanisms of ANP/NPRA and their biological effects involving an increased level of intracellular accumulation of cGMP and a decreased level of cAMP, Ca(2+), and IP3 in different cells and tissue systems.

Citing Articles

ANP Increases Zn Accumulation During Reperfusion in Ex Vivo and In Vivo Hearts.

Ma Y, Laga T, Zhong C, Zhuang B, Quan H, Hong L Curr Med Sci. 2025; 45(1):35-50.

PMID: 40014195 DOI: 10.1007/s11596-025-00019-1.


The RAAS Goodfellas in Cardiovascular System.

Caputo I, Bertoldi G, Driussi G, Cacciapuoti M, Calo L J Clin Med. 2023; 12(21).

PMID: 37959338 PMC: 10649249. DOI: 10.3390/jcm12216873.


Guanylyl cyclase/natriuretic peptide receptor-A: Identification, molecular characterization, and physiological genomics.

Pandey K Front Mol Neurosci. 2023; 15:1076799.

PMID: 36683859 PMC: 9846370. DOI: 10.3389/fnmol.2022.1076799.


Natriuretic Peptides-New Targets for Neurocontrol of Blood Pressure via Baroreflex Afferent Pathway.

Li X, Cui Y, Zhang Q, Li Q, Cheng M, Sun J Int J Mol Sci. 2022; 23(21).

PMID: 36362405 PMC: 9657840. DOI: 10.3390/ijms232113619.


Effects of cGMP/Akt/GSK-3β signaling pathway on atrial natriuretic peptide secretion in rabbits with rapid atrial pacing.

Cao S, Han C, Xuan C, Li X, Wen J, Xu D Front Physiol. 2022; 13:861981.

PMID: 36060704 PMC: 9437264. DOI: 10.3389/fphys.2022.861981.


References
1.
Shi S, Nguyen H, Sharma G, Navar L, Pandey K . Genetic disruption of atrial natriuretic peptide receptor-A alters renin and angiotensin II levels. Am J Physiol Renal Physiol. 2001; 281(4):F665-73. DOI: 10.1152/ajprenal.2001.281.4.F665. View

2.
Holtwick R, Baba H, Ehler E, Risse D, Vobeta M, Gehrmann J . Left but not right cardiac hypertrophy in atrial natriuretic peptide receptor-deficient mice is prevented by angiotensin type 1 receptor antagonist losartan. J Cardiovasc Pharmacol. 2002; 40(5):725-34. DOI: 10.1097/00005344-200211000-00010. View

3.
Berridge M, Irvine R . Inositol phosphates and cell signalling. Nature. 1989; 341(6239):197-205. DOI: 10.1038/341197a0. View

4.
Phillips R, Ardeljan M, Shimabukuro S, Goldman M, Garbowit D, Eison H . Normalization of left ventricular mass and associated changes in neurohormones and atrial natriuretic peptide after 1 year of sustained nifedipine therapy for severe hypertension. J Am Coll Cardiol. 1991; 17(7):1595-602. DOI: 10.1016/0735-1097(91)90654-r. View

5.
Drewett J, Garbers D . The family of guanylyl cyclase receptors and their ligands. Endocr Rev. 1994; 15(2):135-62. DOI: 10.1210/edrv-15-2-135. View